Abstract:The hereditary spastic-ataxia spectrum disorders are a group of rare disabling neurological diseases. The genetic testing process is complex, and often requires multiple different assays to evaluate the many potential causative genes and variant types, including short tandem repeat expansions, single nucleotide variants, insertions/deletions, structural variants and copy number variants. This can be a protracted process and, even after all avenues are exhausted, many individuals do not receive a genetic diagnosis. Aiming to streamline and improve this process, we developed a targeted long-read sequencing strategy with capacity to characterise genetic variation of all types and sizes within 469 disease-associated genes, in a single assay. We applied this to a cohort of 34 individuals with genetically undiagnosed spastic-ataxia spectrum disorders. An additional five individuals with a known genetic diagnosis were included as positive controls. We identified causative pathogenic variants that would be sufficient for genetic diagnosis in 14/34 (41%) unsolved participants. The success rate was 5/11 (45%) in those who were naive to genetic testing and 9/23 (39%) in those who were undiagnosed after prior genetic testing, completed on a clinical basis. Short tandem repeat expansions in FGF14 were the most common cause, present in 7/34 (21%). Two individuals (2/34, 6%) had biallelic pathogenic short tandem repeat expansions in RFC1 and one individual had a monoallelic pathogenic short tandem repeat expansion in ATXN8OS/ATXN8. Causative pathogenic sequence variants other than short tandem repeat expansions were found in four individuals, including a heterozygous missense variant in VCP, a heterozygous in-frame deletion in STUB1, a homozygous splicing variant in ANO10, and compound heterozygous missense and nonsense variants in SPG7. In addition to these solved cases, a pathogenic or likely-pathogenic variant with uncertain clinical implications was identified in a further three individuals, including a single individual who was found to have a short tandem repeat expansion in BEAN1 in addition to biallelic expansions in FGF14 within the range of 200-249 repeats. Our results demonstrate the utility of targeted long-read sequencing in the genetic evaluation of patients with spastic-ataxia spectrum disorders, highlighting both the capacity to increase overall diagnostic yield and to streamline the testing pathway by capturing all known genetic causes in a single assay.

Practical Approach to the Genetic Diagnosis of Unsolved Dystrophinopathies: a Stepwise Strategy in the Genomic Era

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Long‐read Whole‐genome Sequencing for the Genetic Diagnosis of Dystrophinopathies

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations

First Identification of Rare Exonic and Deep Intronic Splice-Altering Variants in Patients With Beta-Sarcoglycanopathy

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

RNA Sequencing Facilitates the Identification of Genetic Causes of Duchenne Muscular Dystrophy and Proposes a Stepwise DMD Diagnostic Procedure

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

Expanding the Molecular Genetic Landscape of Dystrophinopathies and Associated Phenotypes

Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies

[Expert consensus on the genetic diagnosis for Dystrophinopathies]

Genetic Variation Analysis and Treatment Strategy of 20 Patients with Dystrophin Gene Mutations

Molecular Diagnosis of Duchenne Muscular Dystrophy Using Single NGS-Based Assay

Automated DNA Mutation Detection Using Universal Conditions Direct Sequencing: Application to Ten Muscular Dystrophy Genes

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

RNA-seq analysis, targeted long-read sequencing and in silico prediction to unravel pathogenic intronic events and complicated splicing abnormalities in dystrophinopathy

Targeted long-read sequencing as a single assay improves diagnosis of spastic-ataxia disorders

Phenotype-driven genomics enhance diagnosis in children with unresolved neuromuscular diseases

Clinical, Muscle Imaging, and Genetic Characteristics of Dystrophinopathies with Deep-Intronic DMD Variants.